CA-VELODYNE-LIDAR,-INC.
Velodyne Lidar, Inc. today announced Anand Gopalan as its new CEO. Gopalan, who previously was Velodyne’s CTO, assumes the position from Velodyne’s legendary founder David Hall. Hall will continue as full-time Chairman of the Board and remain actively involved in directing the company’s technology, product vision and business strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106006044/en/
Gopalan is a distinguished engineer and technology executive with experience building and leading worldwide engineering organizations. He came to Velodyne in 2016 to form an advanced research and development team. Gopalan leads Velodyne’s customer-focused technology and product development teams to address market needs for lidar solutions designed for high performance, cost optimization and high-volume production.
Over the past three years, Gopalan has worked closely with Hall to develop the company’s technological roadmap and strategic vision. Gopalan is recognized across the industry as a thought leader in business as well as in technology. Recently, Gopalan became more active as a spokesman for the company, expertly explaining the benefits and the workings of lidar to audiences around the world. It is the policy of Velodyne to promote from within the company and Gopalan was a natural choice, having proved himself in 2019.
Gopalan and the Velodyne team look forward to building on the company’s growth trajectory. Due to the breadth and versatility of the Velodyne lidar portfolio, the company continues to make revolutionary contributions to the ever-expanding autonomous industry. Velodyne is a recognized leader in a wide range of markets including automotive, mapping, on-demand mobility, robotics, security, unmanned aerial vehicles (UAV) and more.
Under Gopalan’s leadership alongside Hall, Velodyne brought to market a series of breakthrough lidar products, including the Alpha Prime™, Velarray™, VelaDome™ and a new game-changing lidar sensor, soon to be used for powerful Advanced Driver Assistance Systems (ADAS). Due to its low cost, this sensor will advance automotive safety for the everyday car owner. At CES 2020, Velodyne will unveil the new lidar sensor and Gopalan will discuss his vision for the company at a press conference in the Velodyne booth #7520 on Tuesday, January 7, at 11:00 a.m. PST.
David Hall invented groundbreaking 3D lidar sensor technology in 2005 which set the stage for revolutionizing the automobile industry and was the foundation for Velodyne’s market leadership. The idea of leveraging lidar technology for autonomous driving came to Hall while participating in the DARPA Grand Challenge for autonomous vehicles. Holding more than 30 U.S. patents, Hall is a technology visionary and serial inventor covering a variety of applications, including lidar, audio and marine. The Intellectual Property Owners Education Foundation presented Hall with its 2018 Inventor of the Year Award.
“Anand Gopalan and I have worked side-by-side on Velodyne’s technology roadmap. He is the right executive to lead Velodyne in its next growth phase,” said Hall. “His finger is on the pulse of customer and market needs while possessing the technical brilliance and leadership skills to innovate and deliver. As Chairman, Anand has my full support while I continue to provide vision, strategize and invent.”
“David Hall is more than the founder of Velodyne, he is also the founder of our industry. I am grateful for the trust he has placed in me and excited to lead a company with such a deep history in innovation as Velodyne. We are the forefront of our market, ready to drive the age of autonomy. Velodyne is bringing improved mobility and safety through versatility, responsiveness and agility,” said Gopalan.
Elevating Gopalan to CEO will enhance the leadership team at Velodyne Lidar, running day-to-day business as the company addresses U.S. and global market opportunities. Gopalan and Hall will continue to be supported by a strong bench of Velodyne executive C-staff, including Marta Hall, Chief Marketing Officer (CMO), Rick Tewell, Chief Operating Officer (COO), Mike Jellen, Chief Commercial Officer (CCO), Drew Hamer, Chief Financial Officer (CFO), Barbara Rogan, General Counsel, and Mircea Gradu, Senior Vice President of Product and Quality.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106006044/en/
Contact:
Sean Dowdall Landis Communications Inc. for Velodyne Lidar, Inc. (415) 286-7121 velodyne@landispr.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom